What SYGN did
Synergen Inc.'s insider-dominated board closed ranks to bring back founder and chairman Larry Soll to a fulltime role as CEO, forming a four-man office of the president composed of longtime employees and accepting the resignations of outsiders Jon Saxe as president and CEO and Michael Catalano as vice president of clinical research.
SYGN's four executive vice presidents, who have worked together for about 10 years, will divide functional responsibilities: Kenneth Collins will have finance and administration; Robert Thompson will have oversight of discovery, preclinical and clinical research; Gregory Abbott will be in charge of marketing and sales, business development and legal affairs; and Mark Young will handle process development and manufacturing...